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1. Introduction
The lungs have several characteristics that separate them from other organs; they receive the
total cardiac output, they have two sources of perfusion, pulmonary and bronchial arteries,
and they are exposed to the external environment, making them vulnerable to damage caused
by inhaled microorganisms and airborne particulates. Chronic obstructive pulmonary disease
(COPD), consisting of both chronic bronchitis and emphysema, is caused by inhalation of
tobacco combustion products that cause inflammatory changes that overwhelm the body’s
natural anti-inflammatory defense mechanisms. Inhaled bacteria and viruses lead to infection
and infiltration of polymorphonucleocytes (PMN) whose exo-products including superoxides,
hyopchlorous acid, and elastases damage lung tissue even as they repel the infecting organ‐
isms. Additionally, events such as sepsis and shock can set off a systemic inflammatory cascade
involving the lungs.
Virtually all lung diseases (with the exception of congenital malformations) involve some
degree of inflammation of the airways, the alveoli, or the parenchyma. Given the increasing
recognition of the role of platelets in inflammation, it is not surprising that platelet biology has
become an active area of interest for respirologists around the world. Evidence of this is the
publication in the last several years of comprehensive reviews of platelet and lung biology,
platelets and innate immunity, and the contribution of platelets to specific disorders such as
asthma, acute lung injury, and cystic fibrosis.[1-6] In this chapter we will review the basic
biology of the platelet-lung interaction and work that demonstrates the important part these
cell-like structures play both in maintenance of lung health and in multiple pulmonary
diseases.
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2. Platelet genesis in the lung
Megakaryocytes emerge from the bone marrow and travel to the lung where they are trapped
in the microvasculature and form elongated processes known as proplatelets. Shear forces or
other factors then cause proplatelets to release individual platelets.[7] Platelet release occurs
in bone marrow, but there is mounting evidence that much platelet release from proplatelets
occurs in the pulmonary circulation, making the lungs the birthplace of the platelet.[1]
Evidence supporting this includes the observation of megakaryocytes in pulmonary vascular
beds and an increased number of platelets in pulmonary venous blood as compared to
pulmonary arterial blood. The presence of a large pool of newly formed platelets in the
pulmonary circulation means that there is ample opportunity for interaction with other blood
cells. PMN, which like megakaryocytes have trouble navigating the pulmonary microvascu‐
lature due to their resistance to deformation, accumulate in the pulmonary circuit creating a
pool of marginated white blood cells. This leads to intimate contact between these cells and
the potential for cell-cell interactions.
3. Platelets in Inflammation
Platelets are anucleate cytoplasts that for many years were felt to play a role exclusively in
hemostasis.  More  recent  studies  suggest  that  platelets  also  play  an  important  role  in
inflammation,  including  promoting  the  inflammatory  response  to  influenza  virus.[8,  9]
Platelets are derived from the same myeloid stem cell as traditional inflammatory cells and
therefore have retained the ability to serve as inflammatory cells.  For example they can
undergo chemotaxis,  contain  and release  adhesive  proteins,  activate  other  inflammatory
cells,  release  vasoactive  substances,  and  have  the  capacity  to  express  or  release  pro-
inflammatory  mediators  such  as  thromboxane  (TX)  A2,,  platelet  activating  factor  (PAF),
brain derived neurotrophic factor (BDNF), and platelet factor 4 (PF4, also known as, CXCL4),
as well as a host of other chemokines and chemokine receptors (Table 1).[10-13] Platelets
contain the largest amount of transforming growth factor-β (TGFβ) in the body and express
pattern recognition toll-like receptors.[14] Furthermore,  direct cell-cell  contact by specific
adhesion molecules facilitates transcellular metabolism of arachidonic acid (AA) by both
PMN and platelets.[15,  16]  Platelets  provide  free  AA to  PMN, which enhances  produc‐
tion of PMN-derived leukotriene (LT) B4  and the cysteinyl leukotrienes, LTC4,  LTD4,  and
LTE4.  At  the  same time,  platelet-derived enzymes such as  12-lipoxygenase  act  on PMN
eicosanoid  products  to  produce  other  lipid  mediators,  including  the  anti-inflammatory
lipoxins  (LXs).[17]  Although  platelets  do  not  have  nuclei,  they  do  contain  substantial
amounts of mRNA and are recognized as being capable of de novo synthesis of a growing
number of proteins including adhesion molecules, CD40L, and interleukin-1β.[14, 18, 19]
Platelets are a linking element between hemostasis, inflammation, and tissue repair.[12, 14]
Not only are they activated via traditional pathways (thrombin, adenosine diphosphate (ADP),
TXA2), they can be stimulated by antigens, antigen-antibody complexes, microorganisms, and
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bacterial endotoxins, including lipopolysaccharide from gram negative bacteria such as,
Pseudomonas aeruginosa.[20] Platelet granules store a large number of biologically active
substances that can be released upon activation. It has been suspected that platelets can
undergo differential granule release of pro- or anti-inflammatory mediators depending on
specific circumstances.[14] Release of mediators stored in platelet granules and de novo platelet
production of other mediators can enhance the inflammatory response. Histamine and
serotonin increase vascular permeability; ADP increases the agonist-induced oxidative burst
in PMN; platelet-derived growth factor (PDGF) stimulates chemotaxis for monocytes and
primes eosinophils to produce superoxide anion; and, PF4 induces PMN to adhere to unsti‐
mulated vascular endothelium, induces the release of histamine from basophils, and stimu‐
lates the adherence of eosinophils to vascular walls.[11] Platelets can also release RANTES
(regulated upon activation, normal T-cell expressed and secreted), which plays an important
role in recruitment and adhesion of monocytes to activated endothelium.[21] Once leukocytes
are recruited to tissue, platelets potentiate the inflammatory process by inhibiting apoptosis
of PMN, monocytes, and eosinophils.[22, 23]
Inflammatory
mediator Platelet location Mediator type Inflammatory role
TXA2 Synthesized Eicosanoid
Platelet amplification, Monocyte activation &
T-cell differentiation
IL-1β Synthesized Cytokine Endothelial cell activation
PDGF α-granules Growth factor Neutrophil, monocyte and macrophagerecruitment
PF4 α-granules Chemokine Eosinophil, neutrophil and T- cellrecruitment,
TGF-β α-granules Growth factor Fibroblast and monocyte recruitment
PDHRF α-granules Chemokine Eosinophil recruitment
P-selectin α-granules Selectin receptor
Adhesion of platelets to monocytes,
neutrophils, lymphocytes; complement
activation
CD63 α-granules Tetraspanin receptor Neutrophil, monocyte recruitment
MIP-1α α-granules Cytokine Eosinphil and Neutrophil activation, B-cellimmunoglobulin production
VEGF α-granules Growth factor Lymphocyte & endothelial cell activation
RANTES α-granules Chemokine T-celll & monocyte migration and recruitment
5-HT δ-granules Transmitter Dendritic cell & lymphocyte activation
ADP δ-granules Nucleotide Leukocyte, platelet & endothelial cellactivation
Histamine δ-granules Transmitter Activation of the endothelial cells; increase inpermeability
Glutamate δ-granules Lymphocyte trafficking
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Platelets  metabolize  arachidonic  acid  (AA)  via  the  cyclooxygenase  and  lipoxygenase
pathways to produce inflammatory mediators, the most abundant of which are TXA2, via
the cyclooxygenase pathway, and 12-S-HETE, via the 12-lipoxygenase pathway.[24] Platelet
12-lipoxygenase interacts with the products of AA metabolism by other cells (notably PMN)
to  produce  lipoxins.[17]  In  addition,  PMN stimulated  by  endotoxin  release  PAF,  which
activates platelets,[25] that in turn recruit more PMN to the inflamed area. Platelets also
provide positive feedback mechanisms for their own activation. ADP secreted from dense
granules  and TXA2  formed from AA bind to P2Y and TP receptors  on the platelet  sur‐
face, complete initial platelet activation, and recruit additional platelets into the activated
fraction. Thus, once the inflammatory cascade has been initiated, leukocytes and platelets
combine to propagate and amplify it.
In addition to the active role platelets play in producing inflammatory mediators – and perhaps
even more important – is the role they play in the process of migration of WBC from the
vascular compartment to the site of tissue injury or inflammation. In order for leukocytes to
invade inflamed or infected tissue, the white blood cell must first be tethered to the vessel wall
and roll along the endothelial surface, then attach firmly to the endothelium, and finally
migrate through the endothelium into the tissue. The final two steps, firm attachment and
diapedesis, are the result of up regulation of integrin molecules, particularly integrin αMβ2
(Mac-1, CD11b/CD18). However, tethering and rolling are dependent upon the function of
selectins, especially P-selectin.[26] P-selectin is stored in α-granules of platelets and Weibel-
Palade bodies of endothelial cells, from which it is translocated to the cell surface membrane
upon activation of the cell. Once expressed, P-selectin binds to leukocytes via P-selectin
glycoprotein ligand-1 (PSGL-1).[27] P-selectin glycoprotein ligand-1 is constitutively ex‐
pressed on leukocytes and allows for formation of neutrophil-platelet, monocyte-platelet, and
eosinophil-platelet aggregates if P-selectin is trafficked to platelet cell membranes. Although
endothelial expression of P-selectin alone can lead to leukocyte rolling, this process (which is
a necessary precursor to firm attachment and diapedesis) is much more efficient in the presence
of platelet P-selectin in part due to platelet-leukocyte aggregates which amplify the ability of
WBC to be recruited to the endothelial surface by cross-linking (figure 1).[28] Expression of
platelet membrane P-selectin and release of their chemoattractants enhances leukocyte
recruitment into the lung tissue. The number of platelets adherent to pulmonary vessels (the
marginated pool) need not be large in order to affect vascular permeability and PMN recruit‐
ment. A small number of activated platelets can signal PMN-platelet and platelet-platelet
interactions that lead to an increased number of platelet-PMN aggregates, which can become
tethered to the pulmonary vascular endothelium.
Thus, platelets fit the definition of traditional inflammatory cells in many ways -- they are
capable of phagocytosis and elaboration of pro-inflammatory cytokines, chemokines, and lipid
mediators, and are vital for the process of leukocyte tethering and rolling, which are necessary
fist steps in recruitment of leukocytes to areas of inflammation. Animals made deficient in
platelets or in whom platelet P-selectin is blocked or deficient are less capable of mounting an
inflammatory response and have fewer white blood cells in target organs and humans with
inflammatory processes have increased numbers of platelet-leukocyte aggregates and
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increased expression of platelet P-selectin, both markers of platelet activation.[29, 32] In
summary, platelets are a key component of the inflammatory response in pulmonary tissue.
4. Platelets and lung health
In addition to the pro-inflammatory properties of platelets outlined above, these tiny blood
constituents are essential effector cells in lung hemorrhage and in vascular barrier function.
As reviewed by Weyrich and Zimmerman, platelets play at least 5 roles in maintaining
endothelial barrier function in the pulmonary circulation: release of soluble molecules that
enhance barrier function, physical obstruction of gaps, maintenance of structural features of
endothelial cells, stimulation of endothelial growth, and neutralization of agents that might
enhance endothelial permeability.[1] Thrombocytopenia, therefore, can have a detrimental
effect on barrier function beyond simple hemorrhage. Among the secreted products that
enhance endothelial cell-cell interactions and promote vascular integrity are shingosine-1-
phosphate (S1P), serotonin, and angiopoietin-1. S1P appears to be particularly important in
stabilizing pulmonary endothelium by enhancing adherens junctions and tight junctions.[8]
There is evidence that a critical number of platelets are necessary for basal barrier integrity.
Platelets are also important for vascular repair and remodeling. The vasoactive substances that
Figure 1. Megakaryocytes are found in human lung microvessels and may spawn platelets and platelet precursors in
this location. Reproduced from Weyrich and Zimmerman 2013. Platelets in Lung Biology. Annu. Rev. Physiol.
75:569-91 with permission from Annual Review of Physiology, Volume 75 © 2013 by Annual Reviews.
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platelets release may play protective or damaging roles depending on the circumstances
surrounding platelet activation. Platelets are active effector cells in wound healing and can
also play roles in angiogenesis and vascular repair and remodeling.[33] Some of these actions,
when dysregulated, may lead to pulmonary hypertension, smooth muscle proliferation, and
pathological remodeling of lung tissue.
Figure 2. Platelet activation leading to airway inflammation. 'Reproduced from Page & Pitchford, Platelets Coming of
Age: Implications for Our Understanding of Allergic Inflammation, Am J Respir Crit Care Med 2013;187:459-460, with
permission of the American Thoracic Society. Copyright © 2015 American Thoracic Society.
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5. Platelets and asthma
Over a century ago Sir William Osler recognized that asthma was an inflammatory disease.
Much work has been done since then looking for causes and treatments of airway inflammation
in patients with asthma.[34] However, despite the fact that as long ago as 1967 it was recog‐
nized that platelets could release the vasoactive substance serotonin in response to a hyper‐
sensitivity challenge[35] it is only recently that the importance of platelets in this disease
process has been recognized and explored in detail.
In a series of elegant animal and human experiments spanning more than a decade, investi‐
gators have shown that platelets play a fundamental role in the recruitment of leucocytes to
the lungs following exposure to allergens and play a key role in the onset and perpetuation of
airway inflammation in asthma.[2] Studies have shown that animals deficient in platelets,
platelet receptors, or factors activating platelets have abrogation of responses to allergic
challenges.[29, 32, 36, 37] De Sanctis et al[38] looked at ovalbumin sensitized mice that were
P-selectin deficient and found reduced numbers of eosinophils and lymphocytes in lung lavage
fluid compared to wild type mice, indicating the importance of this platelet-expressed
adhesion molecule in mediating allergen induced pulmonary inflammation. Following this
work, Ulfman and colleagues[39] showed that P-selectin bearing platelets were integral in
tethering of eosinophils to activated endothelium in an ex-vivo perfusion model. Further
studies have shown the importance of platelet P-selectin and soluble P-selectin in eosinophil
attachment to VCAM-1.[40] These authors concluded that their findings were, “...compatible
with a scenario whereby P-selectin, on eosinophil-associated activated platelets or acquired
from plasma or from prior interactions with endothelial cells or platelets, activates eosinophil
α4β1 integrin and stimulates eosinophils to adhere to VCAM-1 and move to the airway in
asthma.”[40] Antibodies that block P-selectin have been shown to decrease leukocyte recruit‐
ment in animal models of asthma and inflammation.[2] P-selectin appears to be a necessary
component of the allergic response in sensitized animals. Platelets also appear to play a role
in causing disease in the lung parenchyma itself, with evidence of platelet diapedesis into lungs
in animals sensitized to allergens.[41] Platelets that have trans-migrated into tissue can then
release their abundant pro-inflammatory mediators and exacerbate allergic inflammation, a
possibility that could explain non-eosinophilc airway inflammation that has been reported in
some human asthmatic patients.
Human studies substantiate the finding of the importance of platelets seen in allergic animal
models. There is a decreased half-life of platelets in atopic patients, implying increased platelet
activation and turnover. Increased circulating neutrophil-platelet aggregates and monocyte-
platelet aggregates have been seen in atopic humans and up to 25% of eosinophils may be
attached to platelets in such subjects.[40] As noted in animal studies, these attachments
increase expression of surface markers (integrins), which enhance leukocyte adhesion to blood
vessels. Moritani and colleagues[42] were able to demonstrate an association between platelet
activation as assessed by P-selectin expression and RANTES release with an asthmatic
diathesis in humans. Similarly, Durk and colleagues[43] have shown increased serotonin in
segmental lavage fluid from asthmatic subjects when challenged locally, implying a role for
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activated platelets, the major source of serotonin in the human lung, in allergic inflammation.
These authors suggest that peripheral serotonin production could be a viable target for future
asthma therapy. Others have shown a temporal relationship between circulating platelet-
derived factors (included soluble P-selectin) and early and late asthmatic response in allergic
subjects. Lommatzsch, et al[10] have looked at another, less well-studied platelet secretion,
brain-derived neurotrophic factor (BDNF). This group found that patients with asthma had
higher levels of BDNF in serum, platelets, and plasma compared to non-asthmatic matched
controls. BNDF levels correlated with parameters of airway obstruction and hyper-reactivity,
making this mediator of neuronal plasticity one more platelet product capable of affecting the
asthmatic airways.
Associations between platelets and metabolites of arachidonic acid have been identified in
asthma patients. Lipoxins play a role in the resolution phase of inflammation and are the
product of interaction between PMN-associated arachidonic acid and platelet-derived 12-
lipoxygenase. Oxidative stress in asthma is correlated with decreased LXA4 in patients with
severe asthma and reflects a loss of anti-inflammatory balance in these patients. In this group
of patients ex-vivo incubation of cells with an inhibitor of LX degradation significantly
inhibited the PAF-induced platelet-leukocyte aggregates in peripheral blood that contribute
to persistent airway inflammation.[44] It is conceivable that drugs that increase LXs or other
Figure 3. Immunocytochemical detection of CFTR in human PLTs (top left: irrelevant antibody; bottom left: anti-CFTR
antibody) and bone marrow megakaryoblasts (top right: irrelevant antibody; bottom right: anti-CFTR antibody). Re‐
produced from Mattosccio et al., Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human
platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J 2010;24:3970-3980. with per‐
mission of the Federation of American Societies for Experimental Biology. © 2010 FASEB
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pro-resolution mediators could offer an alternative or adjunct to corticosteroid therapy in
asthma.
Figure 4. Platelet-leukocyte interactions in respiratory endothelium in acute lung Injury. Platelet activation upregulates
adhesion molecules. (B) Platelets and PMN accumulation in microvasculature is enhanced by fibrin deposition in re‐
sponse to enodthelial injury. (C) Platelets facilitate accumulation of PMN in alveoli and interstitial spaces and contrib‐
ute to alveolar leak syndromes. 'Reproduced from Bozza et al., Amicus or adversary: platelets in lung biology, acute
injury, and inflammation. Am J Respir Cell Mol Biol 2009;40:123-134, with permission of the American Thoracic Soci‐
ety. Copyright © 2015 American Thoracic Society.'
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In a series of human studies specifically looking at aspirin exacerbated respiratory disease,
examination of nasal polyps from aspirin sensitive subjects demonstrated extravascular
platelets adjacent to leukocytes. Platelets appeared to contribute an inordinate amount of
LTC4 synthase activity in these subjects compared to non-aspirin sensitive subjects.[45] LTC4
synthase converts AA-derived LTA4 to the bioactive bronchospastic LTC4. Further mouse
studies by this group have shown a potential role for anti-platelet drugs in aspirin induced
asthma. Reduced production of melatonin by platelets also has been seen in aspirin-sensitive
asthmatics.[46] This deficit could, through several mechanisms, lead to increased platelet
activation and be a factor in these patients’ intolerance to aspirin.
It is possible that the coagulation cascade may also play a role in the airway remodeling seen
in chronic asthmatic patients.[47] Although some early studies using selectin inhibitors have
been reported, human studies of the role of anti-platelet agents in the control of asthma are
lacking. Growing evidence in human and non-human models clearly makes this a promising
area to pursue.
6. Platelets and cystic fibrosis
Cystic fibrosis (CF) is an autosomal-recessive illness that is the most common lethal inherited
disease in the Caucasian population. CF is caused by a mutation in the cystic fibrosis trans‐
membrane conductance regulator (CFTR) gene on the long arm of chromosome 7.[48] The
CFTR protein acts as a chloride and bicarbonate channel, among other functions. Loss of
chloride channel function leads to dehydration of the airway surface liquid, which leads to
thickened airway secretions, chronic respiratory infection, neutrophilic lung infection,
pulmonary destruction, and premature death.[48] The majority of CF patients also have
pancreatic insufficiency, predisposing them to malnutrition and fat-soluble vitamin deficiency.
The CFTR protein acts predominantly as a chloride channel, but plays multiple other roles in
cellular metabolism, including influencing long chain fatty acid synthesis.[49] A hyper-
inflammatory state – whether innately due to CFTR dysfunction or a result of chronic infection
– contributes to lung destruction over time in CF patients. This inflammatory process is
characterized by PMN infiltration of airways and pulmonary parenchyma with elaboration of
free neutrophil elastase and pro-inflammatory cytokines.[50] Platelets play a crucial role in
facilitating the recruitment of PMN into the CF lung, and as active members of the innate
immunity family release their own pro- and anti-inflammatory agents. The process of PMN
recruitment in CF is similar to that described above for asthma.
By the end of the 1980s a number of studies had been performed assessing the function of
platelets from CF patients. These studies were done prior to the discovery of the CFTR gene
and with an incomplete understanding of the underlying molecular defect in these patients.
A better picture of the role of platelets in CF has emerged with improved techniques for
evaluating platelet function and a more complete knowledge of CFTR function.[5, 51] Cross-
sectional studies showing an inverse relationship between platelet activation and pulmonary
function provide evidence for a role for platelets in CF lung disease. These studies have shown
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that: 1) increased platelet numbers correlate with decreased arterial blood oxygen tension
(PaO2),[52] 2) an increase in urinary concentration of thromboxane metabolites (a marker of
platelet activation in vivo) correlates with decreased forced expiratory volume (FEV1),[53, 54]
and 3) increased plasma concentrations of soluble CD40 ligand (sCD40L).[55]
Several groups have demonstrated increased reactivity of CF platelets. Ciabattoni and
colleagues[54] showed enhanced lipid peroxidation, which contributes to platelet activation
in CF patients. They documented increased urinary excretion of TxB2 metabolites and iso‐
prostanes, consistent with oxidative stress and increased arachidonic acid turnover in CF
patients and hypothesized that these factors led to platelet aggregation and activation and
contributes to lung disease in CF patients. O’Sullivan and co-workers[56] showed that washed
platelets from CF subjects express increased agonist-induced surface P-selectin expression (a
marker of platelet activation) compared to those from control subjects. Also, platelets from CF
patients incubated in plasma from non-CF subjects were more reactive to agonists than control
platelets in the same plasma. Even though CF plasma upregulated function of both CF and
non-CF derived platelets, CF patients’ platelets were more reactive than their matched
controls.[56] In addition, McGivern and colleagues demonstrated that CF patients’ platelets
were defective in release of their dense granules. This observation was critical as platelet dense
granules contain many mediators responsible for the recruitment of inflammatory cells. Thus
CF patients may have a muted inflammatory cell mobilization.[57] Together these studies
support platelet activation in CF. Given the known interaction between platelets and leuko‐
cytes in the pulmonary circulation and the abundance of PMN in CF bronchoalveolar lavage
and biopsy/autopy specimens, it is apparent that platelet activation mediates the inflammatory
cell infiltration to at least some degree.
CFTR protein expression was first described in epithelial cells from nasal epithelium and sweat
glands in humans. Since that time, CFTR expression has been identified in circulating blood
cells including PMN, leukocytes, and monocytes. It is feasible that platelets also express CFTR
and that its absence might explain some of the abnormalities in platelet function seen in CF
patients. There have been reports of indirect evidence of loss of CFTR function in CF platelets.
Agam et al.[58] demonstrated abnormal platelet volume changes in response to PGE1,
reflecting down regulation of a cAMP-regulated channel, of which CFTR is one. In another
indirect evaluation of CFTR function in CF platelets, Ulane and collaborators [59] demonstrat‐
ed an intrinsic increase in turnover of platelet membrane phospholipids (specifically, phos‐
phatidylcholine), which they ascribed to CFTR dysfunction. Although CFTR protein and
mRNA have not been detected in control or CF platelets by some investigators,[56] Mattoscio
et al[51] did find evidence of CFTR in platelets and megakaryocytes using flow-cytometry,
immunohistochemical stains, Western blot, and RT-PCR. Elegant studies by this group on CF
platelet proteomics has shown distinct characteristics of CF platelets that predispose them to
promoting pulmonary inflammation. In particular, they showed constitutive overexpression
of beta-3 integrin, which contributes to platelet activation and which can activate the NF-ΚB
pathway in PMN.[60]
Platelets have been found to contain an excess of the long-chain polyunsaturated fatty acid
known as Mead acid.[56] When Mead acid is metabolized by platelet 12-lipoxygenase an end-
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product is generated with PGE2-like activity, which enhances platelet aggregation.[61, 62]
Platelet 12-lipoxygenase also acts on arachidonic acid released from PMN cell membranes to
form members of the anti-inflammatory lipoxin family. CF patients have a defect in lipoxin
synthesis that appears to be directly related to a lack of normal function of CFTR in platelets.
[51] In addition to their anti-inflammatory properties LXs also contribute to maintenance of
normal airway surface liquid depth.[63] Loss of this normal airway lubrication is one of the
fundamental pathogenic features of CF and appears to be exacerbated by the lack of normally
functioning CFTR protein in platelets. Furthermore, cells from respiratory epithelium of CF
patients have a decreased amount of another long chain polyunsaturated fatty acid, docosa‐
hexaenoic acid (DHA).[49] DHA is a precursor to a group of anti-inflammatory compounds
known as resolvins, which are important in leading to the resolution of the normal host
response to infection or injury.[64] Thus, intrinsic defects in CF platelets enhance the inflam‐
matory process, inhibit its resolution, and contribute to the underlying defect in airway surface
liquid. It appears that when normal CFTR function is lost in those with CF results in patients
with CF it results in upregulation of inflammation and a corresponding loss of the counter‐
balancing resolution phase of inflammation.
In addition to intrinsic platelet abnormalities, there is abundant evidence of the presence of
pro-inflammatory mediators in CF patients’ plasma. Increased levels of sCD40L, LTB4,
immune complexes, interleukins, ATP, and tumor necrosis factor-α have all been documented.
[55, 65, 67] It is possible that platelet activation in CF is merely an “innocent bystander” effect
due to the fact that the platelets are immersed in a pool of platelet-activating substances. In
fact, there is evidence that platelets from non-CF subjects are activated when incubated in CF
plasma.[56] Many of these mediators both come from and activate platelets; therefore, it is hard
to know if platelet activation causes inflammation or if inflammation causes platelet activation.
In summary, loss of normal CFTR function can indirectly increase platelet activation through
its affect on plasma factors such as specific cytokines, fatty acids, ATP, and vitamin E, and loss
of CFTR function specifically in platelets can directly increase platelets activation. The final
result, irrespective of cause of activation, is increased recruitment and activation of leukocytes
into the CF lung, elaboration of mediators that cause tissue damage, and enhanced loss of lung
function
7. Platelets and acute lung injury
The acute respiratory distress syndrome (ARDS) is defined as acute onset of hypoxemia in
response to insults including sepsis, trauma, aspiration, and toxins. In 1994 the American-
European Consensus Conference defined ARDS as acute onset of hypoxemia with bilateral
infiltrates on chest roentgenogram and no evidence of left atrial hypertension.[68] The
American-European group defined another entity, acute lung injury (ALI), as similar lung
disease but with a lesser degree of hypoxemia. Although a 2012 task force[68] did not include
ALI as a distinct entity, instead subsuming it in a sub-category of ARDS, many still use the
combined term ALI/ARDS to describe those suffering from acute, severe respiratory distress.
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Despite multiple new therapeutic interventions based on well done clinical trials, mortality in
the most severe category of ARDS still hovers around 50%.[69]
A hallmark of ARDS is increased capillary leak and influx of neutrophils and fluid into the
lung interstitium. Recent reviews have emphasized the role of platelets in instigating this
pulmonary vascular leak.[3, 8] Sepsis and trauma in particular lead to systemic inflammation
and vascular permeability. Interestingly, several of the strategies employed in critical care units
that have led to decreased mortality from ALI/ARDS include interventions that decrease
platelet activation; these include low volume ventilation, nitric oxide administration, and anti-
inflammatory/anti-platelet medications.[3] This insight has led to a trial of the anti-platelet
agent aspirin in ARDS, the Lung Injury Prevention Study with Aspirin.[70]
The interplay between coagulation and inflammation has become an increasingly active area
of investigation in acute lung injury. Activation of the coagulation pathway, including platelet
activation, and decreased fibrinolysis contributes to ALI/ARDS. The maintenance of a normal
endothelial cell barrier is a critical component of the fluid and protein diffusion balance in the
pulmonary circulation. In health, platelets play an important role in systemic and pulmonary
vascular integrity (see above). A number of studies show that platelet depletion can lead to
vascular leakage and that reconstitution with infused platelets can correct the barrier defect
(reviewed in reference 1). Platelets may take up radical oxygen species and release preformed
mediators such as serotonin, which contribute to endothelial barrier stability. Among these
mediators is sphingosine 1-phosphate (S1P), a lipid growth factor that promotes endothelial
integrity and which may be a therapeutic agent in capillary leak syndromes.[71, 72] Thus,
platelets – by direct thrombotic action and through release of specific mediators – can provide
protection of respiratory function by decreasing the likelihood of capillary leak in response to
injurious effectors.
Platelets may provide a degree of protection for the injured lung through their hemostatic
mechanisms; however, observations suggest a negative role for platelets in experimental
alveolar injury. A hallmark of ALI/ARDS pathology is the presence of microthrombi in the
pulmonary circulation. Studies have shown increased numbers of platelets and leukocytes in
pulmonary capillaries and platelet-fibrin thrombi have been detected in autopsy specimens
from patients dying of ALI/ARDS.[3] Thrombocytopenia is a poor prognostic factor in sepsis
and may represent sequestering of activated platelets in the microcirculation.[3] Post-mortem
and biopsy samples have shown thrombi within pulmonary arteries, arterioles, and capillaries
from patients suffering from ALI/ARDS and can explain in part the ventilation-perfusion
mismatching that contributes to the severe hypoxemia seen clinically.[73] These thrombi are
the result of activation of platelet hemostatic mechanisms, which have the capability to be both
beneficial and harmful to an ill patient. Activated human platelets synthesize tissue factor and
provide signals that induce tissue factor production by monocytes.[8] Tissue factor then leads
to formation of microthrombi and clots that then occlude pulmonary vessels. The ability to
inhibit thrombus formation may explain some of the clinical effect of inhaled nitric oxide (NO)
in critically ill patients. NO has been shown to decrease platelet aggregation and improve
oxygenation in a small cohort of ALI/ARDS patients, which the investigators attributed to its
anti-thrombotic effect[74] and in vitro studies by another group showed an NO dose-depend‐
Platelets, Inflammation and Respiratory Disease
http://dx.doi.org/10.5772/60569
147
ent decrease in ADP and collagen induced platelet aggregation, P-selectin expression, and
fibrinogen binding.[75] NO administration to ALI/ARDS patients demonstrated similar
reductions in platelet aggregation and P-selecting expression. It is possible that the transient
in oxygenation seen with NO administration lies in part in its anti-platelet action and not just
as a vasodilator.
Systemic inflammation caused by sepsis activates circulating cells and leads to formation of
heterotypic aggregates.[76] These platelet-leukocyte interactions lead to production and
release of factors that can disrupt vascular integrity. The major effector cell in ALI/ARDS is
the PMN, which causes endothelial damage, plasma leakage, and hypoxemia.[77] The
importance of neutrophils in syndromes of acute alveolar damage is underscored by animal
studies where lung injury is abolished by induction of neutropenia. Since platelets play such
a key role in PMN tethering and rolling it is not surprising that they play an active role in the
inflammatory process accompanying ALI/ARDS. Since platelets are integral to PMN tethering
and rolling it is not surprising that they play an active role in sepsis. Using a mouse model of
sepsis-induced ALI caused by inhaled lipopolysaccharide (LPS) Grommes and colleagues[78]
demonstrated that animals deficient in either platelets or neutrophils had marked reduction
in neutrophilic infiltration and protein/fluid leak into alveoli. In separate experiments these
investigators depleted either platelets or neutrophils. Further work showed that treatment
with monoclonal antibodies to the platelet-derived chemokines CCL5 and CXCL4 led to
decreased neutrophil recruitment, plasma exudation, and protease release. The mechanism
for this pulmonary protection appeared to be disruption of the platelet-leukocyte heteromers
formed by these chemokines. Surprisingly, these authors did not find that blocking adhesion
molecules commonly associated with platelet-neutrophil aggregation, specifically P-selectin
and GPIIb/IIIa, led to decreased diffuse alveolar damage.
Although the work by Grommes et al implicated CCL5 and CXCL4 and not P-selectin as the
critical surface markers in heterotypic aggregate formation, others found that selective
disruption of platelet P-selectin led to decreased platelet-PMN aggregates, decrease TXA2
release, and decreased lung injury in an acid-induced model of ALI.[79] Further evidence of
the fundamental role of platelet-leukocyte aggregates in ALI/ARDS comes from work by Ortiz-
Munoz and colleagues[80] who showed that the aspirin-induced LX, 15-epi-lipoxin A4, has a
protective effect in LPS induced lung injury through its ability to disrupt heterotypic aggregate
formation. Using intravital microscopy they were able to show formation of platelet-neutrophil
aggregates in response to LPS administration and a sharp decline in aggregate formation,
platelet activation, and lung injury following aspirin administration.[80] Thus a large number
of studies indicate the importance of activated platelets and platelet-leukocyte aggregates in
the development of ALI/ARDS in animal models. Evidence of P-selectin upregulation on the
surface of circulating platelets in humans with ALI/ARDS supports the theory that these
cytoplasts play and active role in human disease, too.[3, 30] Patients with sepsis have been
shown to have increased surface P-selectin expression on platelets and increased plasma levels
of products of α-granule release.[76] It is well recognized that expression of P-selectin is a
marker of platelet activation and, the animal study of Grommes et al[78] not withstanding,
leads to formation of platelet-leukocytes heterotypic aggregates. Although this likely repre‐
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sents an adaptive mechanism of enhancing leukocyte recruitment to areas of infection or injury,
a maladaptive consequence of platelet activation is the tissue injury and alveolar leakage that
results from release of their cytoplasmic contents and recruitment of activated PMN.
LPS from gram-negative bacteria is a potent activator of platelets and platelet-leukocyte
aggregates. In addition to producing mediators that can trigger platelet activation, both gram-
negative and gram-positive bacteria can interact directly with platelets. In their thrombotic
role, platelets adhere to exposed sub-endothelial matrix at the site of vascular injury as the first
line of defense against hemorrhage. This places them in perfect position to act as sentinels
against invading microorganisms. In fact, platelets are now recognized as part of the innate
immune system patrolling the endothelium and capable of rapid release of an array of
immunomodulatory cytokines.6 Furthermore, platelets express toll-like receptors and inter‐
actions with bacteria through these pattern recognition receptors can lead to aggregation and/
or activation of platelets directly, or indirectly through the action of plasma proteins.[4, 81]
Infected thrombi formed by bacterial-platelet adhesion can seed the microcirculation of the
lung or stick to exposed surfaces such as damaged heart valves.[82] Human platelets can
engulf, but do not kill bacteria due to a lack of myeloperoxidase and their inability to form
“killing chambers” isolated from the cytoplasm and the cell’s exterior.[83] However, upon
activation at the site of endothelial injury, platelet granules release thrombin-inducible platelet
microbiocidal proteins, which act against a broad range of microbes. The released anti-
microbial proteins include platelet activating factor-4 (CXCL4), RANTES, and β-defensins.[6,
82] Platelets then have a Janus-like character acting either for the betterment or detriment of
the host; which it is depends on the timing and location of the stimulus. Platelet activation and
release of anti-microbial proteins may halt invasion by bacteria or may cause tissue damage
by upregulating inflammation by recruiting and activating more platelets, leukocytes, and
heterotypic aggregates. Recent work implicates a specific single nucleotide polymorphism
linked to platelets, which is associated with ARDS risk at least partially mediated via effects
on platelet count. [84]
There is growing evidence implicating the role of neutrophil extracellular traps (NETs) in the
genesis of lung damage in sepsis.[81, 85] NETs are extracellular lattices, which are capable of
capturing and killing bacteria. Clark et al[81] were able to show that NETs are released from
PMN in response to binding of platelet TLR4 to neutrophil TLR4 ligand but that stimulation
of PMN with bacterial LPS in the absence of platelets did not induce NET release. Presumably
an aspect of the innate immune system that protect organisms from bacterial infection, NETs
are primarily released in small capillaries and are capable of causing damage to endothelial
tissue. Whereas platelets contribute to the integrity of the endothelial barrier and promote
bacterial killing, they also promote endothelial damage directly by release of their own pre-
formed and rapidly transcripted mRNA products and from activation of leukocytes, whose
inflammatory products and NETs have adverse effects on the pulmonary parenchyma.
Transfusion related acute lung injury (TRALI) is the leading cause of transfusion-related
mortality and is defined as acute lung injury that occurs during or within 6 hours of transfusion
of one or more units of blood or blood components.[86] Known risk factors for developing
TRALI include several recipient factors indicative of severity of underlying illness (including
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high pressure mechanical ventilation, a trigger for platelet activation) and donor factors such
as female sex, HLA class II antibodies, and volume of anti-human neutrophil antigens.[86]
Patients with TRALI have evidence of systemic inflammation with increases in circulating
neutrophils and a decrease in platelets compared with controls, similar to those with the
systemic inflammatory response syndrome seen in sepsis.[87] It is likely that TRALI is caused
by infusion of anti-neutrophil antibodies and/or biologically active lipids (potentially platelet
derived) that interact with recipient neutrophils that are already primed by the underlying
illness.[8, 88] Activation of platelets and neutrophils then leads to the cascade of endothelial
injury and permeability seen in other forms of acute lung injury. A study showed that infusion
of stored platelet concentrates, rich in lipid mediators, could cause ALI when infused into rats
pretreated with LPS.[88] Treatment with aspirin, which induces lipid mediator such as LXs
with antagonistic actions on platelet activation and platelet-neutrophil aggregation, abrogated
the TRALI response in a murine model of TRALI.[80]
8. Platelets and chronic obstructive pulmonary disease
The vast majority of studies on chronic bronchitis and emphysema have focused on the role
of tobacco smoke exposure as the causative agent. Clinical trials tend to look at the effect of
various bronchodilators or antibiotics in the treatment of COPD exacerbations. However,
dampening the response to the inciting constituents of tobacco smoke has the potential to
alleviate many of the downstream consequences of cigarette smoking. A handful of studies
have examined platelet counts and platelet volumes in COPD, with sometimes contradictory
results.[89, 90] PMN have been shown to play a fundamental role in the development and
progression of COPD and their transmigration across pulmonary endothelium is critical to
their function in COPD.[91, 92] The process of activation of platelets and adherence of
inflammatory cells to pulmonary endothelium is enhanced by cigarette smoke.[93] Given the
role of PMN in the destructive nature of COPD and the known role of platelets in facilitating
transmigration of these cells in the pulmonary circulation, it is intuitive to believe that platelets
must play a role in COPD just as they do in asthma and CF.
9. Summary
Platelets clearly play a major role in the development of multiple acute lung injury syndromes
including transfusion-related pulmonary problems. Activation and aggregation of platelets
plays a crucial role in the recruitment and activation of leukocytes to the site of lung injury/
infection. Additionally, platelets are part of the innate immune system and are capable of
triggering immune responses via release of pro-inflammatory cytokines and chemokines. It is
not surprising, therefore, that they are an integral part of the inflammatory cascade in a host
of pulmonary diseases. In addition to the specific processes discussed in detail in this chapter,
platelets are undoubtedly active participants in a myriad of other lung processes that involve
cellular infiltration and tissue destruction. The platelet is ubiquitous in pulmonary disease
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genesis and sustainability. Further work with platelet inhibitors, specific and non-specific, may
lead to novel approaches to therapy of chronic and acute lung disease.
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